SCHEMBL6658719

SCHEMBL6658719

CC(C)(C)NS(=O)(=O)c1ccc(OBOc2ccc(S(=O)(=O)NC(C)(C)C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
MAPT P10636 2/20 0.53
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA12 O43570 1/20 0.49
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
CA9 Q16790 1/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
MAPK1 P28482 1/20 0.49
LMNA P02545 4/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
PARG Q86W56 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10769588 0.81 CA1 (0.61) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL8478768 0.80 MAPT (0.61) ALDH1A1SMN1; SMN2MAPTLMNAKDM4E
SCHEMBL4050348 0.79 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2CA1CA2CA12
SCHEMBL16060627 0.77 FFAR4 (0.57) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL20988466 0.77 PGR (0.56) ALDH1A1SMN1; SMN2MAPTLMNAKDM4E
SCHEMBL12169369 0.77 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL4041550 0.75 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2MAPTCYP2C9MAPK1
SCHEMBL23345377 0.75 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL15840367 0.75 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTCA1CA2
SCHEMBL634085 0.75 ALDH1A1 (0.79) ALDH1A1SMN1; SMN2MAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1012142-B1 2,3,5-TRISUBSTITUTED PYRIDINES AS INHIBITORS OF CYCLOOXYGENASE-2 MERCK FROSST CANADA INC (CA) 2004-08-11 EP disclosed
EP-1140941-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-10-10 EP disclosed
WO-2000039131-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-07-06 WO disclosed
US-6046217-A TREATING AN INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT COMPRISING ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A NONTOXIC 3-PHENYL SUBSTITUTED PYRIDINES MERCK FROSST CANADA & CO. (CA) 2000-04-04 US disclosed